Hemophilia Treatment Market by Product and Type- Global Industry Analysis & Forecast to 2027
Published On : March 2020 Pages : 180 Category: Pharma & Healthcare Report Code : HC0410160
Hemophilia Treatment Market by Product (Plasma Derived Coagulation Factor Concentrate, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics), by Type (Hemophilia A, Hemophilia B, Hemophilia C) - Global Industry Analysis & Forecast to 2027
Industry Outlook and Trend Analysis
The Hemophilia Treatment Market has encountered significant development over the recent years and is anticipated to grow tremendously over the forecast period. Hemophilia is inherited bleeding disorders that cause abnormal or exaggerated bleeding and poor blood clotting. This disease is inherited by an X-linked recessive genetic pattern, so males are commonly affected while females are usually carriers of the disease. This mutations causes genes that code for proteins that are essential in the blood clotting process. The bleeding symptoms arise because blood clotting is impaired.
Drivers and Restraints
Top-down and bottom-up approaches are used to validate the global market and estimate the market size for company, regions segments, type segments and applications (end users). In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub segments listed in this report. Extensive qualitative and further quantitative analysis is also done from all the numbers arrived at in the complete market engineering process to list key information throughout the report.
Regional Insights
The data for 2021 is an estimate, based on the history data and the integrated view of industry experts, manufacturers, distributors and end users etc.
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Southeast Asia
- Rest of Asia-Pacific
- South America
- Brazil
- Argentina
- Columbia
- Rest of South America
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Nigeria
- South Africa
- Rest of MEA
Competitive Analysis
The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and share of the overall industry.
-
- Baxter International, Inc.
- Grifols SA
- CSL Ltd.
- Octapharma AG
- Novo Nordisk
- Kedrion
- Pfizer, Inc.
- Bayer AG
- Biogen Idec, Inc.
- Hospira, Inc
Some of the key questions answered by the report are:
- What was the market size in 2017 and forecast from 2021 to 2027?
- What will be the industry market growth from 2017 to 2027?
- What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
- What are the major segments leading the market growth and why?
- Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?
Market Classification
· Hemophilia Treatment Market, By Product, Estimates and Forecast, 2017-2027 ($Million)
o Plasma Derived Coagulation Factor Concentrate
o Recombinant Coagulation Factor Concentrates
o Desmopressin
o Antifibrinolytics
· Hemophilia Treatment Market, By Type, Estimates and Forecast, 2017-2027 ($Million)
o Hemophilia A
o Hemophilia B
o Hemophilia C
· Hemophilia Treatment Market, By Key Players, Estimates and Forecast, 2017-2027 ($Million)
o Baxter International, Inc.
o Grifols SA
o CSL Ltd.
o Octapharma AG
o Novo Nordisk
o Kedrion
o Pfizer, Inc.
o Bayer AG
o Biogen Idec, Inc.
o Hospira, Inc
· Hemophilia Treatment Market, By Region, Estimates and Forecast, 2017-2027 ($Million)
o North America
§ North America Submarine Cables Market, By Country
o U.S. Submarine Cables Market
o Canada Submarine Cables Market
o Mexico Submarine Cables Market
o Europe
§ Europe Submarine Cables Market, By Country
o Germany Submarine Cables Market
o UK Submarine Cables Market
o France Submarine Cables Market
o Russia Submarine Cables Market
o Italy Submarine Cables Market
o Rest of Europe Submarine Cables Market
o Asia-Pacific
§ Asia-Pacific Submarine Cables Market, By Country
o China Submarine Cables Market
o Japan Submarine Cables Market
o South Korea Submarine Cables Market
o India Submarine Cables Market
o Southeast Asia Submarine Cables Market
o Rest of Asia-Pacific Submarine Cables Market
o South America
§ South America Submarine Cables Market
o Brazil Submarine Cables Market
o Argentina Submarine Cables Market
o Columbia Submarine Cables Market
o Rest of South America Submarine Cables Market
o Middle East and Africa
§ Middle East and Africa Submarine Cables Market
o Saudi Arabia Submarine Cables Market
o UAE Submarine Cables Market
o Egypt Submarine Cables Market
o Nigeria Submarine Cables Market
o South Africa Submarine Cables Market
o Rest of MEA Submarine Cables Market
Table of Contents:
1. Introduction
1.1. Report Description
2. Executive Summary
2.1. Key Highlights
3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
4. Market Analysis by Regions
4.1. North America (United States, Canada and Mexico)
4.1.1. United States Market Status and Outlook (2017-2027)
4.1.2. Canada Market Status and Outlook (2017-2027)
4.1.3. Mexico Market Status and Outlook (2017-2027)
4.2. Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
4.2.1. Germany Market Status and Outlook (2017-2027)
4.2.2. France Market Status and Outlook (2017-2027)
4.2.3. UK Market Status and Outlook (2017-2027)
4.2.4. Russia Market Status and Outlook (2017-2027)
4.2.5. Italy Market Status and Outlook (2017-2027)
4.2.6. Rest of Europe Market Status and Outlook (2017-2027)
4.3. Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)
4.3.1. China Market Status and Outlook (2017-2027)
4.3.2. Japan Market Status and Outlook (2017-2027)
4.3.3. Korea Market Status and Outlook (2017-2027)
4.3.4. India Market Status and Outlook (2017-2027)
4.3.5. Southeast Asia Market Status and Outlook (2017-2027)
4.3.6. Rest of Asia-Pacific Market Status and Outlook (2017-2027)
4.4. South America (Brazil, Argentina, Columbia and Rest of South America)
4.4.1. Brazil Market Status and Outlook (2017-2027)
4.4.2. Argentina Market Status and Outlook (2017-2027)
4.4.3. Columbia Market Status and Outlook (2017-2027)
4.4.4. Rest of South America Market Status and Outlook (2017-2027)
4.5. Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)
4.5.1. Saudi Arabia Market Status and Outlook (2017-2027)
4.5.2. United Arab Emirates Market Status and Outlook (2017-2027)
4.5.3. Egypt Market Status and Outlook (2017-2027)
4.5.4. Nigeria Market Status and Outlook (2017-2027)
4.5.5. South Africa Market Status and Outlook (2017-2027)
4.5.6. Turkey Market Status and Outlook (2017-2027)
4.5.7. Rest of Middle East and Africa Market Status and Outlook (2017-2027)
5. Hemophilia Treatment Market, By Product
5.1. Introduction
5.2. Global Hemophilia Treatment Revenue and Market Share by Product (2017-2021)
5.2.1. Global Hemophilia Treatment Revenue and Revenue Share by Product (2017-2021)
5.3. Plasma Derived Coagulation Factor Concentrate
5.3.1. Global Plasma Derived Coagulation Factor Concentrate Revenue and Growth Rate (2017-2021)
5.4. Recombinant Coagulation Factor Concentrates
5.4.1. Global Recombinant Coagulation Factor Concentrates Revenue and Growth Rate (2017-2021)
5.5. Desmopressin
5.5.1. Global Desmopressin Revenue and Growth Rate (2017-2021)
5.6. Antifibrinolytics
5.6.1. Global Antifibrinolytics Revenue and Growth Rate (2017-2021)
6. Hemophilia Treatment Market, By Type
6.1. Introduction
6.2. Global Hemophilia Treatment Revenue and Market Share by Type (2017-2021)
6.2.1. Global Hemophilia Treatment Revenue and Revenue Share by Type (2017-2021)
6.3. Hemophilia A
6.3.1. Global Hemophilia A Revenue and Growth Rate (2017-2021)
6.4. Hemophilia B
6.4.1. Global Hemophilia B Revenue and Growth Rate (2017-2021)
6.5. Hemophilia C
6.5.1. Global Hemophilia C Revenue and Growth Rate (2017-2021)
7. Hemophilia Treatment Market, By Region
7.1. Introduction
7.2. Global Hemophilia Treatment Revenue and Market Share by Regions
7.2.1. Global Hemophilia Treatment Revenue by Regions (2017-2021)
7.3. North America Hemophilia Treatment by Countries
7.3.1. North America Hemophilia Treatment Revenue and Growth Rate (2017-2021)
7.3.2. North America Hemophilia Treatment Revenue (Million USD) by Countries (2017-2021)
7.3.3. United States
7.3.3.1. United States Hemophilia Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.3.4. Canada
7.3.4.1. Canada Hemophilia Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.3.5. Mexico
7.3.5.1. Mexico Hemophilia Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.4. Europe Hemophilia Treatment by Countries
7.4.1. Europe Hemophilia Treatment Revenue and Growth Rate (2017-2021)
7.4.2. Europe Hemophilia Treatment Revenue (Million USD) by Countries (2017-2021)
7.4.3. Germany
7.4.3.1. Germany Hemophilia Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.4. France
7.4.4.1. France Hemophilia Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.5. UK
7.4.5.1. UK Hemophilia Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.6. Russia
7.4.6.1. Russia Hemophilia Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.7. Italy
7.4.7.1. Italy Hemophilia Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.8. Rest of Europe
7.4.8.1. Rest of Europe Hemophilia Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.5. Asia-Pacific Hemophilia Treatment by Countries
7.5.1. Asia-Pacific Hemophilia Treatment Revenue and Growth Rate (2017-2021)
7.5.2. Asia-Pacific Hemophilia Treatment Revenue (Million USD) by Countries (2017-2021)
7.5.3. China
7.5.3.1. China Hemophilia Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.4. Japan
7.5.4.1. Japan Hemophilia Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.5. Korea
7.5.5.1. Korea Hemophilia Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.6. India
7.5.6.1. India Hemophilia Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.7. Southeast Asia
7.5.7.1. Southeast Asia Hemophilia Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.8. Rest of Asia-Pacific
7.5.8.1. Rest of Asia-Pacific Hemophilia Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.6. South America Hemophilia Treatment by Countries
7.6.1. South America Hemophilia Treatment Revenue and Growth Rate (2017-2021)
7.6.2. South America Hemophilia Treatment Revenue (Million USD) by Countries (2017-2021)
7.6.3. Brazil
7.6.3.1. Brazil Hemophilia Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.6.4. Argentina
7.6.4.1. Argentina Hemophilia Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.6.5. Columbia
7.6.5.1. Columbia Hemophilia Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.6.6. Rest of South America
7.6.6.1. Rest of South America Hemophilia Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.7. Middle East and Africa Hemophilia Treatment by Countries
7.7.1. Middle East and Africa Hemophilia Treatment Revenue and Growth Rate (2017-2021)
7.7.2. Middle East and Africa Hemophilia Treatment Revenue (Million USD) by Countries (2017-2021)
7.7.3. Saudi Arabia
7.7.3.1. Saudi Arabia Hemophilia Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.4. United Arab Emirates
7.7.4.1. United Arab Emirates Hemophilia Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.5. Egypt
7.7.5.1. Egypt Hemophilia Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.6. Nigeria
7.7.6.1. Nigeria Hemophilia Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.7. South Africa
7.7.7.1. South Africa Hemophilia Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.8. Turkey
7.7.8.1. Turkey Hemophilia Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.9. Rest of Middle East and Africa
7.7.9.1. Rest of Middle East and Africa Hemophilia Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
8. Company Profiles
8.1. Baxter International, Inc.
8.1.1. Business Overview
8.1.2. Service Portfolio
8.1.3. Strategic Developments
8.1.4. Financial Overview
8.2. Grifols SA
8.2.1. Business Overview
8.2.2. Service Portfolio
8.2.3. Strategic Developments
8.2.4. Financial Overview
8.3. CSL Ltd.
8.3.1. Business Overview
8.3.2. Service Portfolio
8.3.3. Strategic Developments
8.3.4. Financial Overview
8.4. Octapharma AG
8.4.1. Business Overview
8.4.2. Service Portfolio
8.4.3. Strategic Developments
8.4.4. Financial Overview
8.5. Novo Nordisk
8.5.1. Business Overview
8.5.2. Service Portfolio
8.5.3. Strategic Developments
8.5.4. Financial Overview
8.6. Kedrion
8.6.1. Business Overview
8.6.2. Service Portfolio
8.6.3. Strategic Developments
8.6.4. Financial Overview
8.7. Pfizer, Inc.
8.7.1. Business Overview
8.7.2. Service Portfolio
8.7.3. Strategic Developments
8.7.4. Financial Overview
8.8. Bayer AG
8.8.1. Business Overview
8.8.2. Service Portfolio
8.8.3. Strategic Developments
8.8.4. Financial Overview
8.9. Biogen Idec, Inc.
8.9.1. Business Overview
8.9.2. Service Portfolio
8.9.3. Strategic Developments
8.9.4. Financial Overview
9. Hemophilia Treatment Market Forecast (2022-2027)
9.1. Global Hemophilia Treatment Revenue (Millions USD) and Growth Rate (2022-2027)
9.2. Hemophilia Treatment Market Forecast by Regions (2022-2027)
9.2.1. North America Hemophilia Treatment Market Forecast (2022-2027)
9.2.1.1. United States Hemophilia Treatment Market Forecast (2022-2027)
9.2.1.2. Canada Hemophilia Treatment Market Forecast (2022-2027)
9.2.1.3. Mexico Hemophilia Treatment Market Forecast (2022-2027)
9.2.2. Europe Hemophilia Treatment Market Forecast (2022-2027)
9.2.2.1. Germany Hemophilia Treatment Market Forecast (2022-2027)
9.2.2.2. France Hemophilia Treatment Market Forecast (2022-2027)
9.2.2.3. UK Hemophilia Treatment Market Forecast (2022-2027)
9.2.2.4. Russia Hemophilia Treatment Market Forecast (2022-2027)
9.2.2.5. Italy Hemophilia Treatment Market Forecast (2022-2027)
9.2.2.6. Rest of Europe Hemophilia Treatment Market Forecast (2022-2027)
9.2.3. Asia-Pacific Hemophilia Treatment Market Forecast (2022-2027)
9.2.3.1. China Hemophilia Treatment Market Forecast (2022-2027)
9.2.3.2. Japan Hemophilia Treatment Market Forecast (2022-2027)
9.2.3.3. Korea Hemophilia Treatment Market Forecast (2022-2027)
9.2.3.4. India Hemophilia Treatment Market Forecast (2022-2027)
9.2.3.5. Southeast Asia Hemophilia Treatment Market Forecast (2022-2027)
9.2.3.6. Rest of Asia-Pacific Hemophilia Treatment Market Forecast (2022-2027)
9.2.4. South America Hemophilia Treatment Market Forecast (2022-2027)
9.2.4.1. Brazil Hemophilia Treatment Market Forecast (2022-2027)
9.2.4.2. Argentina Hemophilia Treatment Market Forecast (2022-2027)
9.2.4.3. Columbia Hemophilia Treatment Market Forecast (2022-2027)
9.2.4.4. Rest of South America Hemophilia Treatment Market Forecast (2022-2027)
9.2.5. Middle East and Africa Hemophilia Treatment Market Forecast (2022-2027)
9.2.5.1. Saudi Arabia Hemophilia Treatment Market Forecast (2022-2027)
9.2.5.2. United Arab Emirates Hemophilia Treatment Market Forecast (2022-2027)
9.2.5.3. Egypt Hemophilia Treatment Market Forecast (2022-2027)
9.2.5.4. Nigeria Hemophilia Treatment Market Forecast (2022-2027)
9.2.5.5. South Africa Hemophilia Treatment Market Forecast (2022-2027)
9.2.5.6. Turkey Hemophilia Treatment Market Forecast (2022-2027)
9.2.5.7. Rest of Middle East and Africa Hemophilia Treatment Market Forecast (2022-2027)
9.3. Hemophilia Treatment Market Forecast by Product (2022-2027)
9.3.1. Hemophilia Treatment Forecast by Product (2022-2027)
9.3.2. Hemophilia Treatment Market Share Forecast by Product (2022-2027)
9.4. Hemophilia Treatment Market Forecast by Type (2022-2027)
9.4.1. Hemophilia Treatment Forecast by Type (2022-2027)
9.4.2. Hemophilia Treatment Market Share Forecast by Type (2022-2027)
List of Tables
List of Tables and Figures:
Figure United States Hemophilia Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Canada Hemophilia Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Mexico Hemophilia Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Germany Hemophilia Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure France Hemophilia Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure UK Hemophilia Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Russia Hemophilia Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Italy Hemophilia Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of Europe Hemophilia Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure China Hemophilia Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Japan Hemophilia Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Korea Hemophilia Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure India Hemophilia Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Southeast Asia Hemophilia Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of Asia-Pacific Hemophilia Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Brazil Hemophilia Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Argentina Hemophilia Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Columbia Hemophilia Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of South America Hemophilia Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Saudi Arabia Hemophilia Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure United Arab Emirates Hemophilia Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Egypt Hemophilia Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Nigeria Hemophilia Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure South Africa Hemophilia Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Turkey Hemophilia Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of Middle East and Africa Hemophilia Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Table Global Hemophilia Treatment Revenue and Revenue Share by Product (2017-2019)
Figure Global Plasma Derived Coagulation Factor Concentrate Revenue and Growth Rate (2017-2019)
Figure Global Recombinant Coagulation Factor Concentrates Revenue and Growth Rate (2017-2019)
Figure Global Desmopressin Revenue and Growth Rate (2017-2019)
Figure Global Antifibrinolytics Revenue and Growth Rate (2017-2019)
Table Global Hemophilia Treatment Revenue and Revenue Share by Type (2017-2019)
Figure Global Hemophilia A Revenue and Growth Rate (2017-2019)
Figure Global Hemophilia B Revenue and Growth Rate (2017-2019)
Figure Global Hemophilia C Revenue and Growth Rate (2017-2019)
Table Global Hemophilia Treatment Revenue by Regions (2017-2019)
Figure North America Hemophilia Treatment Growth Rate (2017-2019)
Figure North America Hemophilia Treatment Revenue and Growth Rate (2017-2019)
Figure North America Hemophilia Treatment by Countries (2017-2019)
Figure North America Hemophilia Treatment Revenue (Million USD) by Countries (2017-2019)
Figure United States Hemophilia Treatment Growth Rate (2017-2019)
Figure United States Hemophilia Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Canada Hemophilia Treatment Growth Rate (2017-2019)
Figure Canada Hemophilia Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Mexico Hemophilia Treatment Growth Rate (2017-2019)
Figure Mexico Hemophilia Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Europe Hemophilia Treatment Growth Rate (2017-2019)
Figure Europe Hemophilia Treatment Revenue and Growth Rate (2017-2019)
Figure Europe Hemophilia Treatment by Countries (2017-2019)
Figure Europe Hemophilia Treatment Revenue (Million USD) by Countries (2017-2019)
Figure Germany Hemophilia Treatment Growth Rate (2017-2019)
Figure Germany Hemophilia Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure France Hemophilia Treatment Growth Rate (2017-2019)
Figure France Hemophilia Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure UK Hemophilia Treatment Growth Rate (2017-2019)
Figure UK Hemophilia Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Russia Hemophilia Treatment Growth Rate (2017-2019)
Figure Russia Hemophilia Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Italy Hemophilia Treatment Growth Rate (2017-2019)
Figure Italy Hemophilia Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of Europe Hemophilia Treatment Growth Rate (2017-2019)
Figure Rest of Europe Hemophilia Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Asia-Pacific Hemophilia Treatment Growth Rate (2017-2019)
Figure Asia-Pacific Hemophilia Treatment Revenue and Growth Rate (2017-2019)
Figure Asia-Pacific Hemophilia Treatment by Countries (2017-2019)
Figure Asia-Pacific Hemophilia Treatment Revenue (Million USD) by Countries (2017-2019)
Figure China Hemophilia Treatment Growth Rate (2017-2019)
Figure China Hemophilia Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Japan Hemophilia Treatment Growth Rate (2017-2019)
Figure Japan Hemophilia Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Korea Hemophilia Treatment Growth Rate (2017-2019)
Figure Korea Hemophilia Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure India Hemophilia Treatment Growth Rate (2017-2019)
Figure India Hemophilia Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Southeast Asia Hemophilia Treatment Growth Rate (2017-2019)
Figure Southeast Asia Hemophilia Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of Asia-Pacific Hemophilia Treatment Growth Rate (2017-2019)
Figure Rest of Asia-Pacific Hemophilia Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure South America Hemophilia Treatment Growth Rate (2017-2019)
Figure South America Hemophilia Treatment Revenue and Growth Rate (2017-2019)
Figure South America Hemophilia Treatment by Countries (2017-2019)
Figure South America Hemophilia Treatment Revenue (Million USD) by Countries (2017-2019)
Figure Brazil Hemophilia Treatment Growth Rate (2017-2019)
Figure Brazil Hemophilia Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Argentina Hemophilia Treatment Growth Rate (2017-2019)
Figure Argentina Hemophilia Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Columbia Hemophilia Treatment Growth Rate (2017-2019)
Figure Columbia Hemophilia Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of South America Hemophilia Treatment Growth Rate (2017-2019)
Figure Rest of South America Hemophilia Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Middle East and Africa Hemophilia Treatment Growth Rate (2017-2019)
Figure Middle East and Africa Hemophilia Treatment Revenue and Growth Rate (2017-2019)
Figure Middle East and Africa Hemophilia Treatment by Countries (2017-2019)
Figure Middle East and Africa Hemophilia Treatment Revenue (Million USD) by Countries (2017-2019)
Figure Saudi Arabia Hemophilia Treatment Growth Rate (2017-2019)
Figure Saudi Arabia Hemophilia Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure United Arab Emirates Hemophilia Treatment Growth Rate (2017-2019)
Figure United Arab Emirates Hemophilia Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Egypt Hemophilia Treatment Growth Rate (2017-2019)
Figure Egypt Hemophilia Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Nigeria Hemophilia Treatment Growth Rate (2017-2019)
Figure Nigeria Hemophilia Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure South Africa Hemophilia Treatment Growth Rate (2017-2019)
Figure South Africa Hemophilia Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Turkey Hemophilia Treatment Growth Rate (2017-2019)
Figure Turkey Hemophilia Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of Middle East and Africa Hemophilia Treatment Growth Rate (2017-2019)
Figure Rest of Middle East and Africa Hemophilia Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Table Baxter International, Inc. Hemophilia Treatment Financial Overview
Table Grifols SA Hemophilia Treatment Financial Overview
Table CSL Ltd. Hemophilia Treatment Financial Overview
Table Octapharma AG Hemophilia Treatment Financial Overview
Table Novo Nordisk Hemophilia Treatment Financial Overview
Table Kedrion Hemophilia Treatment Financial Overview
Table Pfizer, Inc. Hemophilia Treatment Financial Overview
Table Bayer AG Hemophilia Treatment Financial Overview
Table Biogen Idec, Inc. Hemophilia Treatment Financial Overview
Figure Global Hemophilia Treatment Revenue (Millions USD) and Growth Rate (2019-2027)
Table Hemophilia Treatment Market Forecast by Regions (2019-2027)
Figure North America Hemophilia Treatment Market Forecast (2019-2027)
Figure United States Hemophilia Treatment Market Forecast (2019-2027)
Figure Canada Hemophilia Treatment Market Forecast (2019-2027)
Figure Mexico Hemophilia Treatment Market Forecast (2019-2027)
Figure Europe Hemophilia Treatment Market Forecast (2019-2027)
Figure Germany Hemophilia Treatment Market Forecast (2019-2027)
Figure France Hemophilia Treatment Market Forecast (2019-2027)
Figure UK Hemophilia Treatment Market Forecast (2019-2027)
Figure Russia Hemophilia Treatment Market Forecast (2019-2027)
Figure Italy Hemophilia Treatment Market Forecast (2019-2027)
Figure Rest of Europe Hemophilia Treatment Market Forecast (2019-2027)
Figure Asia-Pacific Hemophilia Treatment Market Forecast (2019-2027)
Figure China Hemophilia Treatment Market Forecast (2019-2027)
Figure Japan Hemophilia Treatment Market Forecast (2019-2027)
Figure Korea Hemophilia Treatment Market Forecast (2019-2027)
Figure India Hemophilia Treatment Market Forecast (2019-2027)
Figure Southeast Asia Hemophilia Treatment Market Forecast (2019-2027)
Figure Rest of Asia-Pacific Hemophilia Treatment Market Forecast (2019-2027)
Figure South America Hemophilia Treatment Market Forecast (2019-2027)
Figure Brazil Hemophilia Treatment Market Forecast (2019-2027)
Figure Argentina Hemophilia Treatment Market Forecast (2019-2027)
Figure Columbia Hemophilia Treatment Market Forecast (2019-2027)
Figure Rest of South America Hemophilia Treatment Market Forecast (2019-2027)
Figure Middle East and Africa Hemophilia Treatment Market Forecast (2019-2027)
Figure Saudi Arabia Hemophilia Treatment Market Forecast (2019-2027)
Figure United Arab Emirates Hemophilia Treatment Market Forecast (2019-2027)
Figure Egypt Hemophilia Treatment Market Forecast (2019-2027)
Figure Nigeria Hemophilia Treatment Market Forecast (2019-2027)
Figure South Africa Hemophilia Treatment Market Forecast (2019-2027)
Figure Turkey Hemophilia Treatment Market Forecast (2019-2027)
Figure Rest of Middle East and Africa Hemophilia Treatment Market Forecast (2019-2027)
Figure Global Hemophilia Treatment Forecast by Product (2019-2027)
Figure Global Hemophilia Treatment Market Share Forecast by Product (2019-2027)
Figure Global Hemophilia Treatment Forecast by Product (2019-2027)
Figure Global Hemophilia Treatment Forecast by Type (2019-2027)
Figure Global Hemophilia Treatment Market Share Forecast by Type (2019-2027)
Figure Global Hemophilia Treatment Forecast by Type (2019-2027)
Please Note: Data related to the Companies are subject to Availability.
Research Methodology
We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.
Data Mining
Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.
Data Collection Matrix
|
Data Collection Matrix |
Supply Side |
Demand Side |
|
Primary Data Sources |
|
|
|
Secondary Data Sources |
|
|
Market Modeling and Forecasting
We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.
- Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
- Number of patients for particular device or medical procedure and
- Repeated use of particular device depending on health and condition of patient
- Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.
We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.
Data Validation
We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.
Data Triangulation
Industry Analysis
|
Qualitative Data |
Quantitative Data (2017-2025) |
|
|